Peptide LibraryFat Loss & Metabolism
🔥
9 Peptides

Fat Loss & Metabolism

The GLP-1 revolution just hit a new peak. From FDA-approved standards like Ozempic and Mounjaro to the record-breaking Retatrutide Phase 3 data announced in December 2025, this is the most rapidly advancing area in all of metabolic medicine. Every peptide here is backed by human clinical trial data.

Featured — Latest Phase 3 Data
Phase 3 Data Just In — December 2025
LY3437943 · Triple Agonist

Retatrutide

The world's first triple hormone receptor agonist — activating GLP-1, GIP, and glucagon simultaneously. In the TRIUMPH-4 Phase 3 trial, participants lost an average of 28.7% of body weight (71.2 lbs) over 68 weeks. That is the most powerful weight loss result ever recorded in a large-scale clinical trial.

GLP-1 ReceptorGIP ReceptorGlucagon ReceptorNot Yet FDA Approved
View Full Profile Compare vs. Tirzepatide
28.7%
Body weight lost (TRIUMPH-4 Phase 3)
71.2 lbs
Average weight lost over 68 weeks
58%
Achieved ≥25% weight loss on 12 mg dose
All Fat Loss & Metabolism Peptides
FDA Approved · Oral Option

Semaglutide

Ozempic

The breakthrough GLP-1 agonist for sustainable weight loss

Significant and sustained weight loss (15–20% body weight)
Reduces appetite and food cravings
Improves blood sugar regulation
0.5–2.4 mg per weekFull Profile
FDA Approved

Tirzepatide

Mounjaro

The dual-receptor agonist that outperformed every GLP-1 drug in clinical trials

Up to 20.9% body weight loss in 72 weeks (SURMOUNT-1)
Average of 52 lbs lost at the highest dose
Significant A1C reduction (up to 2.3%) in type 2 diabetes
5–15 mg per week (maintenance)Full Profile

Tesamorelin

Egrifta

FDA-approved GHRH analog for visceral fat reduction

Reduces visceral (abdominal) fat significantly
Improves body composition
Increases IGF-1 levels
1–2 mg per dayFull Profile

AOD-9604

Anti-Obesity Drug 9604

A fragment of HGH specifically targeting fat metabolism

Stimulates fat breakdown (lipolysis)
Inhibits fat formation (lipogenesis)
Does not affect blood sugar or IGF-1 levels
300 mcg per dayFull Profile

AOD-9604

Anti-Obesity Drug 9604

A growth hormone fragment that targets fat loss without the side effects of HGH

Stimulates lipolysis (fat breakdown) without affecting blood sugar
Inhibits lipogenesis (new fat formation)
Does not affect IGF-1 levels, avoiding growth-related side effects
300 mcg per dayFull Profile

Cagrilintide

AM833

Long-acting amylin analog with additive weight loss when combined with semaglutide

Appetite suppression via amylin receptor activation
Slowed gastric emptying
Glucagon suppression
1.2 mg once weeklyFull Profile

Tesofensine

NS2330

Triple monoamine reuptake inhibitor with potent appetite suppression and weight loss

Potent appetite suppression
Increased energy expenditure
Significant body weight reduction
0.5 mg once dailyFull Profile

5-Amino-1MQ

5-Amino-1-methylquinolinium

NNMT inhibitor that promotes fat oxidation inside adipocytes without appetite suppression

Adipocyte size reduction
Fat oxidation promotion
Metabolic rate enhancement
50-100 mg once dailyFull Profile